ONCY
Oncolytics Biotech Inc. NASDAQ Listed Oct 5, 2001$0.90
Pre-mkt
$0.92
+1.85%
Mkt Cap $90.3M
52w Low $0.33
48.3% of range
52w High $1.51
50d MA $0.99
200d MA $1.05
P/E (TTM)
-2.9x
EV/EBITDA
-2.8x
P/B
—
Debt/Equity
-0.1x
ROE
757.0%
P/FCF
-4.2x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$0.99
200d MA
$1.05
Avg Volume
1.3M
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
322 11th Avenue SW · Calgary, AB T2R 0C5 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.06 | -0.08 | -33.3% | 0.81 | +0.6% | +5.4% | +9.6% | +3.2% | -1.1% | -5.3% | — |
| Nov 12, 2025 | AMC | -0.12 | -0.10 | +16.7% | 1.14 | -2.6% | -5.3% | -3.7% | +1.0% | -1.9% | +1.0% | — |
| Aug 8, 2025 | AMC | -0.11 | -0.05 | +54.5% | 0.86 | -2.1% | +1.1% | -0.8% | +18.6% | -7.8% | +14.9% | — |
| May 14, 2025 | AMC | -0.09 | -0.06 | +33.3% | 0.52 | -3.0% | -3.4% | -6.5% | -4.9% | -3.4% | -2.0% | — |
| Mar 7, 2025 | AMC | -0.08 | -0.07 | +12.5% | 0.69 | -1.3% | -6.8% | -4.6% | +2.8% | -1.1% | +0.3% | — |
| Nov 12, 2024 | AMC | -0.08 | -0.09 | -12.5% | 1.12 | -1.8% | -8.0% | -1.9% | -3.0% | +1.5% | +6.5% | — |
| Aug 1, 2024 | AMC | -0.08 | -0.07 | +12.5% | 1.03 | +0.0% | -1.0% | -4.6% | +3.7% | -1.5% | -1.0% | — |
| May 9, 2024 | AMC | -0.09 | -0.07 | +22.2% | 1.24 | +0.0% | -5.6% | +0.0% | +0.9% | -1.7% | -2.6% | — |
| Mar 7, 2024 | AMC | -0.11 | -0.04 | +63.6% | 1.04 | +2.9% | +1.0% | +1.0% | +0.0% | -1.9% | -1.9% | — |
| Nov 3, 2023 | AMC | -0.07 | -0.10 | -42.9% | 1.72 | +0.0% | -5.2% | -1.8% | -1.9% | -15.9% | +9.8% | — |
| Aug 14, 2023 | AMC | -0.09 | -0.09 | +0.0% | 2.05 | -0.5% | +0.5% | -3.9% | +0.0% | +8.1% | +2.3% | — |
| May 5, 2023 | AMC | -0.07 | -0.07 | +0.0% | 1.60 | +0.6% | +6.9% | -4.7% | +0.0% | -1.2% | +0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.04 | $1.06 | +1.9% | +1.0% | -1.9% | +1.0% | -4.7% | +0.9% |
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.43 | $0.42 | -2.3% | -2.0% | -4.5% | +4.1% | -4.2% | -6.4% |
| May 16 | Jones Trading | Downgrade | Buy → Hold | — | $0.50 | $0.49 | -1.9% | -6.5% | -4.9% | -3.4% | -2.0% | -4.5% |
| Mar 10 | RBC Capital | Maintains | Outperform → Outperform | — | $0.69 | $0.68 | -1.3% | -6.8% | -4.6% | +2.8% | -1.1% | +0.3% |
| Mar 10 | Maxim Group | Maintains | Buy → Buy | — | $0.69 | $0.68 | -1.3% | -6.8% | -4.6% | +2.8% | -1.1% | +0.3% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.69 | $0.68 | -1.3% | -6.8% | -4.6% | +2.8% | -1.1% | +0.3% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.73 | $0.71 | -3.0% | -4.7% | +3.2% | +3.3% | +7.3% | -2.3% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.04 | +1.0% | -1.9% | -3.0% | +1.5% | +6.5% | -5.8% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.93 | $0.94 | +1.1% | +2.2% | -2.7% | -1.6% | -1.0% | -0.0% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.95 | $0.95 | +0.0% | +0.0% | +0.0% | +4.2% | -2.1% | -0.2% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.17 | $1.17 | +0.0% | +0.9% | -1.7% | -2.6% | -1.8% | +0.9% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.04 | $1.07 | +2.9% | +1.0% | +1.0% | +0.0% | -1.9% | -1.9% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.05 | $1.05 | +0.0% | +9.5% | +0.9% | +0.0% | -2.6% | -9.7% |
| Jan 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.17 | $1.19 | +1.7% | +3.4% | +2.5% | -0.8% | -2.4% | +4.2% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.33 | $1.30 | -2.3% | -1.5% | -3.8% | +7.9% | -8.8% | -1.6% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.45 | $1.45 | +0.0% | -3.4% | +4.3% | +1.4% | -4.7% | +6.4% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.06 | $2.05 | -0.5% | -3.9% | +0.0% | +8.1% | +2.3% | +6.4% |
| Jun 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.42 | $2.46 | +1.7% | +8.3% | -0.8% | +20.4% | -1.0% | +0.3% |
| Jun 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.52 | $2.58 | +2.4% | +8.7% | -2.6% | -7.9% | -1.6% | +8.3% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.58 | $1.60 | +1.3% | +0.6% | -0.6% | -1.9% | +18.1% | +12.0% |
| May 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.16 | $2.14 | -0.9% | -19.0% | -1.7% | -5.8% | +2.5% | +3.6% |
| May 24 | JonesTrading | Maintains | Buy → Buy | — | $1.79 | $1.80 | +0.6% | +20.1% | +0.5% | -19.0% | -1.7% | -5.8% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.24 | $1.24 | +0.0% | +4.8% | +2.3% | +7.5% | -5.6% | -4.4% |
| Mar 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.59 | $1.60 | +0.6% | -1.9% | -3.8% | -6.7% | -5.0% | -6.8% |
| Oct 6 | Maxim Group | Maintains | Buy → Buy | — | $1.27 | $1.26 | -0.8% | +0.8% | -0.8% | -3.9% | +1.6% | +1.6% |
| Feb 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.01 | $4.66 | +54.8% | +18.3% | -1.7% | -3.1% | -2.7% | +13.0% |
| May 11 | RBC Capital | Maintains | Outperform → Outperform | — | $1.71 | $1.75 | +2.3% | +21.6% | -4.3% | +4.0% | -2.4% | +1.5% |
| Sep 12 | Needham | Maintains | Buy → Buy | — | $26.79 | $26.98 | +0.7% | -2.1% | +4.7% | -2.8% | +3.2% | -0.7% |
| Mar 4 | PiperJaffray | Maintains | Overweight → Overweight | — | $31.92 | $32.30 | +1.2% | +2.7% | -6.1% | -0.9% | -3.1% | +1.9% |
| Dec 18 | Bloom Burton & Co. | Downgrade | Buy → Hold | — | $32.11 | $32.68 | +1.8% | +0.6% | +3.5% | +0.6% | -0.8% | +1.7% |
| Sep 12 | Bloom Burton & Co. | Maintains | Buy → Buy | — | $26.79 | $23.75 | -11.3% | -12.1% | +2.0% | -5.2% | -2.1% | +3.0% |
| Aug 30 | Stifel Nicolaus | Maintains | Buy → Buy | — | $25.08 | $28.03 | +11.8% | +4.9% | -3.6% | +3.0% | -0.4% | -1.1% |
No insider trades available.
8-K · 8.01
!! High
Oncolytics Biotech Inc. -- 8-K 8.01: Material Event / Announcement
Oncolytics Biotech filed a material event disclosure but the specific announcement details are not provided in the summary, limiting investors' ability to assess the significance of this development.
May 4
8-K · 8.01
!! High
Oncolytics Biotech, Inc. Common Shares -- 8-K 8.01: Material Event / Announcement
Oncolytics Biotech received FDA guidance to proceed with a controlled randomized pivotal trial for its therapy in anal squamous cell carcinoma, potentially advancing the company toward regulatory approval and commercialization.
Apr 27
8-K
Unknown — 8-K Filing
ONCY faces potential dilution from a shelf registration that allows the company to issue shares at management's discretion, pressuring stock price unless used strategically for acquisitions or debt reduction.
Apr 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Oncolytics Biotech (ONCY) may advance pelareorep toward FDA approval for anal cancer, potentially opening a new revenue stream if the pivotal trial succeeds and regulators accept the single-arm study design.
Apr 6
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Oncolytics Biotech's domestication restructuring involved board changes and officer appointments, likely signaling operational reorganization that could affect leadership direction and shareholder governance structures.
Apr 1
8-K
Unknown — 8-K Filing
Directors gain broad indemnification coverage for legal expenses and settlements, which may reduce accountability for questionable decisions and increase shareholder litigation risk and governance concerns.
Mar 26
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
Oncolytics Biotech amended its bylaws, which could affect shareholder voting rights, board procedures, or governance structure—investors should review details to understand any changes impacting voting power or corporate control.
Mar 20
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Oncolytics' pelareorep advancing to two AACR presentations suggests clinical progress in multiple cancer indications, potentially validating the immunotherapy's broad applicability and supporting future financing or partnership prospects.
Mar 19
8-K · 8.01
!! High
Oncolytics Biotech, Inc. Common Shares -- 8-K 8.01: Material Event / Announcement
Oncolytics Biotech filed a material event disclosure, though the specific announcement details are referenced in the attached exhibit rather than disclosed in the filing itself.
Mar 2
8-K · 8.01
!! High
Oncolytics Biotech, Inc. Common Shares -- 8-K 8.01: Material Event / Announcement
Oncolytics Biotech completed enrollment in its GOBLET gastrointestinal cancer study, potentially moving the clinical program toward data readout and regulatory milestone achievement.
Feb 24
8-K · 8.01
!! High
Oncolytics Biotech, Inc. Common Shares -- 8-K 8.01: Material Event / Announcement
Oncolytics Biotech's pelareorep received FDA designation for the FOLFIRI combination in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, potentially expanding its clinical development pathway.
Feb 4
Data updated apr 26, 2026 5:29pm
· Source: massive.com